These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10730322)

  • 1. [Bio-equivalence and generic drugs. Studies of bio-equivalence. II. Special situations. Reflections on problems which may arise with drugs habitually used in neurology].
    Zapater P; Horga JF
    Rev Neurol; 2000 Jan 16-31; 30(2):146-54. PubMed ID: 10730322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalence of generic and brand-name drugs for cardiovascular disease.
    Zema MJ
    JAMA; 2009 Apr; 301(16):1654-5; author reply 1655-6. PubMed ID: 19383949
    [No Abstract]   [Full Text] [Related]  

  • 3. Equivalence of generic and brand-name drugs for cardiovascular disease.
    Carter BL
    JAMA; 2009 Apr; 301(16):1654; author reply 1655-6. PubMed ID: 19383950
    [No Abstract]   [Full Text] [Related]  

  • 4. Bioequivalence of controlled-release calcium antagonists.
    Schall R; Müller FR; Müller FO; Luus HG
    Clin Pharmacokinet; 1997 Jan; 32(1):75-89. PubMed ID: 9012557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence and narrow therapeutic index drugs.
    Benet LZ; Goyan JE
    Pharmacotherapy; 1995; 15(4):433-40. PubMed ID: 7479195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic equivalence of complex drugs.
    Schellekens H; Klinger E; Mühlebach S; Brin JF; Storm G; Crommelin DJ
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):176-83. PubMed ID: 20951177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
    Berg MJ; Gross RA; Tomaszewski KJ; Zingaro WM; Haskins LS
    Neurology; 2008 Aug; 71(7):525-30. PubMed ID: 18695164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
    Lui KJ; Chang KC
    Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equivalence trials: methodologic analysis.
    Carneiro A
    Rev Port Cardiol; 2003 Sep; 22(9):1125-39. PubMed ID: 14655314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on the bioequivalence and therapeutic equivalence of generic formulations: An overview of the landscape.
    Perry R
    Clin Ther; 2010 Sep; 32(10):1796-7. PubMed ID: 21194603
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
    Tsai YS; Lan SK; Ou JH; Tzai TS
    Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic substitution--is it safe in patients at high cardiovascular risk?
    Rayner B; Buchanan-Lee B; Brink J; Opie L
    S Afr Med J; 2002 Aug; 92(8):603-4. PubMed ID: 12244616
    [No Abstract]   [Full Text] [Related]  

  • 17. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical and economic impact of generic drugs in the treatment of epilepsy].
    Argumosa A; Herranz JL
    Rev Neurol; 2005 Jul 1-15; 41(1):45-9. PubMed ID: 15999330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic cyclosporine formulations: more open questions than answers.
    Cattaneo D; Perico N; Remuzzi G
    Transpl Int; 2005 Apr; 18(4):371-8. PubMed ID: 15773953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of pharmacokinetic interaction as an equivalence problem.
    Steinijans VW; Hartmann M; Huber R; Radtke HW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S63-8. PubMed ID: 1601534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.